These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England. Perrio MJ; Wilton LV; Shakir SA Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762 [TBL] [Abstract][Full Text] [Related]
4. [No progress without the physician in therapy of obesity]. Schmidt H; Plauth M MMW Fortschr Med; 2000 Jan; 142(4):35-6. PubMed ID: 10850095 [No Abstract] [Full Text] [Related]
5. Long-term pharmacotherapy for obesity. Klein S Obes Res; 2004 Dec; 12 Suppl():163S-6S. PubMed ID: 15687412 [TBL] [Abstract][Full Text] [Related]
6. Comparison of metabolic effects of orlistat and sibutramine treatment in Type 2 diabetic obese patients. Derosa G; Cicero AF; Murdolo G; Ciccarelli L; Fogari R Diabetes Nutr Metab; 2004 Aug; 17(4):222-9. PubMed ID: 15575343 [TBL] [Abstract][Full Text] [Related]
7. Sibutramine is safe and effective for weight loss in obese patients whose hypertension is well controlled with angiotensin-converting enzyme inhibitors. McMahon FG; Weinstein SP; Rowe E; Ernst KR; Johnson F; Fujioka K; J Hum Hypertens; 2002 Jan; 16(1):5-11. PubMed ID: 11840224 [TBL] [Abstract][Full Text] [Related]
8. Efficacy and safety of sibutramine for weight loss in obese patients with hypertension well controlled by beta-adrenergic blocking agents: a placebo-controlled, double-blind, randomised trial. Sramek JJ; Leibowitz MT; Weinstein SP; Rowe ED; Mendel CM; Levy B; McMahon FG; Mullican WS; Toth PD; Cutler NR J Hum Hypertens; 2002 Jan; 16(1):13-9. PubMed ID: 11840225 [TBL] [Abstract][Full Text] [Related]
9. Sibutramine-induced acute myocardial infarction in a young lady. Yim KM; Ng HW; Chan CK; Yip G; Lau FL Clin Toxicol (Phila); 2008 Nov; 46(9):877-9. PubMed ID: 18788006 [TBL] [Abstract][Full Text] [Related]
10. Use of sibutramine to treat obesity. Ryan DH Prim Care; 2003 Jun; 30(2):405-26, viii. PubMed ID: 14567156 [TBL] [Abstract][Full Text] [Related]
11. Elevation of QT dispersion after obesity drug sibutramine. Yalcin AA; Yavuz B; Ertugrul DT; Algul B; Yilmaz H; Deveci OS; Kucukazman M; Ata N; Demirel G; Dal K; Tutal E J Cardiovasc Med (Hagerstown); 2010 Nov; 11(11):832-5. PubMed ID: 20671571 [TBL] [Abstract][Full Text] [Related]
12. The obesity pandemic--how did we get here? Malone M Ann Pharmacother; 2007 Sep; 41(9):1497-8. PubMed ID: 17652122 [No Abstract] [Full Text] [Related]
13. Safety assessment of an anti-obesity drug (sibutramine): a retrospective cohort study. Tyczynski JE; Oleske DM; Klingman D; Ferrufino CP; Lee WC Drug Saf; 2012 Aug; 35(8):629-44. PubMed ID: 22788234 [TBL] [Abstract][Full Text] [Related]
14. Acute myocardial infarction in a 24 year-old man possibly associated with sibutramine use. Eroglu E; Gemici G; Bayrak F; Kalkan AK; Degertekin M Int J Cardiol; 2009 Oct; 137(2):e43-5. PubMed ID: 18687492 [TBL] [Abstract][Full Text] [Related]
15. Influence of Sibutramine on blood pressure: evidence from placebo-controlled trials. Jordan J; Scholze J; Matiba B; Wirth A; Hauner H; Sharma AM Int J Obes (Lond); 2005 May; 29(5):509-16. PubMed ID: 15685250 [TBL] [Abstract][Full Text] [Related]
16. [32-year-old patient with acute myocardial infarction possibly induced by the appetite suppressant sibutramine]. Pöss J; Böhm M; Link A Dtsch Med Wochenschr; 2010 May; 135(19):965-8. PubMed ID: 20446231 [TBL] [Abstract][Full Text] [Related]
17. Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. James WP; Caterson ID; Coutinho W; Finer N; Van Gaal LF; Maggioni AP; Torp-Pedersen C; Sharma AM; Shepherd GM; Rode RA; Renz CL; N Engl J Med; 2010 Sep; 363(10):905-17. PubMed ID: 20818901 [TBL] [Abstract][Full Text] [Related]
18. Withdrawal of sibutramine. Editorial is judgment in advance of the facts. Finer N; BMJ; 2010 Mar; 340():c1346. PubMed ID: 20219799 [No Abstract] [Full Text] [Related]